378
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer

, , , , , , & show all
Pages 25-36 | Received 12 May 2021, Accepted 30 Nov 2021, Published online: 20 Dec 2021
 

Abstract

Aim

To prepare the hyaluronic acid-coated Olaparib-loaded PEI − PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect.

Methods

The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining.

Results

The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (−16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice.

Conclusions

According to the results, the Ola-loaded and HA-coated PEI − PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment.

Acknowledgement

The authors would like to thank ZouYunyun from Shiyanjia Lab (www.shiyanjia.com) for the TEM analysis.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was financially supported by the National Natural Science Foundation of China [82073402], Traditional Chinese Medicine Scientific Research Project of Health Commission of Hubei Province [ZY2021M007].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.